Bionano Genomics Inc. (NASDAQ:BNGO) finished Friday with a subtraction of -$0.02 to close at $3.99, a downside of -0.50 percent. An average of 1,454,980 shares of common stock have been traded in the last five days. There was a fall of -$0.86 in the past week, and it reached a new high 2 times over the past 12 months. The last 20 days have seen an average of 1,127,406 shares traded, while the 50-day average volume stands at 1,152,933.
BNGO stock has decreased by -38.88% in the last month. The company shares reached their 1-month lowest point of $3.67 on 08/10/23. With the stock rallying to its 52-week high on 02/02/23, shares of the company touched a low of $3.67 and a high of $43.50 in 52 weeks. It has reached a new high 8 times so far this year and lost -72.67% or -$10.61 in price. In spite of this, the price is down -90.83% from the 52-week high.
Insider Transactions
BNGO stock investors should be aware that Bionano Genomics Inc. (BNGO) stock had its last reported insider trading activity 362 days ago on Jun 13.
Valuation Metrics
Bionano Genomics Inc. (BNGO) stock’s beta is 2.19. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 5.03, the price-to-book (PB) ratio at 5.18.
Financial Health
The quick ratio of Bionano Genomics Inc. for the three months ended June 29 was 2.90, and the current ratio was 3.70, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.02 and a total debt to equity ratio of 0.02 for the quarter ending June 29. Bionano Genomics Inc.’s EBITDA margin for the year ending June 29 is -429.76%. Its gross profit as reported stood at $5.95 million compared to revenue of $27.8 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Bionano Genomics Inc.’s return on assets was -44.90%.
Earnings Surprise
For the three-month period that ended June 29, Bionano Genomics Inc. had $62.21 million in cash. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$38.91 million in the quarter, while revenues of -$37.12 million were grew 17.35%. The analyst consensus anticipated Bionano Genomics Inc.’s latest quarter earnings to come in at -$1.03 per share, but it turned out to be -$1.24, a -20.40% surprise. For the quarter, EBITDA amounted to -$36.03 million. Shareholders own equity worth $35.35 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Bionano Genomics Inc. (BNGO) price momentum. RSI 9-day as of the close on 11 August was 21.01%, suggesting the stock is oversold, with historical volatility in this time frame at 115.48%.
As of today, BNGO’s price is $4.17 -17.73% or -$0.86 from its 5-day moving average. BNGO is currently trading -38.43% lower than its 20-day SMA and -63.06% lower than its 100-day SMA. However, the stock’s current price level is -42.33% below the SMA50 and -80.15% below the SMA200.
The stochastic %K and %D were 13.38% and 13.67%, respectively, and the average true range (ATR) was 0.46. With the 14-day stochastic at 12.70% and the average true range at 0.45, the RSI (14) stands at 25.35%. The stock has reached -0.78 on the 9-day MACD Oscillator while the 14-day reading was at -1.12.
Analyst Ratings
Scotiabank launched coverage on Bionano Genomics Inc. (NASDAQ: BNGO) in its analyst report released on January 05, 2023. The firm assigned the stock a Sector outperform rating. The consensus rating for Bionano Genomics Inc. (BNGO) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell BNGO, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 6 others rate it as a “buy”.
What is BNGO’s price target for the next 12 months?
Analysts predict a range of price targets between $9.00 and $32.00, with a median target of $18.75. Taking a look at these predictions, the average price target given by analysts for Bionano Genomics Inc. (BNGO) stock is $19.75.
